Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViiV’s Potential HIV Blockbuster Among Latest Drugs To Win EMA Nod

Executive Summary

A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.

Advertisement

Related Content

EU Ultomiris Approval Rounds Off A Good Week For Alexion’s Complement Franchise
ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients
EU Biosimilar Filings, Opinions And Approvals
European CHMP Opinions and MAA Updates
A Successful Failure? Lartruvo’s Speedy Withdrawal Sets New Bar For Accelerated Approval Drugs
New EU Market Hopefuls Await Their Fate; EMA Re-Adopting Zynteglo Opinion
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
Keeping Track Of The US FDA's Final Approvals Of 2018

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel